Japan Anemia Drugs Market Analysis

Japan Anemia Drugs Market Analysis


$ 3999

Japan's Anemia drugs market was valued at $993 Mn in 2022 and is estimated to expand at a CAGR of 9.40% from 2022-30 and will reach $2038 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and the aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are Pfizer, Astellas Pharma, Takeda Pharmaceutical, Daiichi Sankyo Company, Chugai Pharmaceutical, Otsuka Holdings, Roche, and GSK among others.

ID: IN10JPPH008 CATEGORY: Pharmaceuticals GEOGRAPHY: Japan AUTHOR: Nandini Shah

Buy Now

Japan Anemia Drugs Market Executive Summary

The Japan Anemia Drugs market was valued at $993 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 9.40% from 2022 to 2030 and will reach $2038 Mn in 2030. Anemia is a condition in which the number of red blood cells or the concentration of hemoglobin in them is lower than usual. Hemoglobin is required to carry oxygen, and if you have too few or malformed red blood cells, or not enough hemoglobin, your blood's capacity to carry oxygen to the body's tissues will be reduced. Symptoms include weariness, weakness, dizziness, and shortness of breath, among others. The ideal hemoglobin concentration required to meet physiologic needs varies according to age, gender, elevation, smoking habits, and pregnancy status. Nutritional deficiencies, mainly iron deficiency, though deficits in folate, vitamins B12 and A are also key causes; hemoglobinopathies; and infectious illnesses, such as malaria, TB, HIV, and parasite infections are the most common causes of anemia.

The report shows that in 2019, the sales of anemia drugs in Japan reached 269.7 billion yen, an increase of 4.4% compared to the previous year. The market is mainly driven by the aging population and the increasing prevalence of chronic kidney disease, which is a common cause of anemia. In terms of the types of anemia drugs, erythropoiesis-stimulating agents (ESAs) are the most commonly prescribed. In 2019, ESAs accounted for 80.6% of the total sales of anemia drugs in Japan. Other types of anemia drugs include iron supplements, vitamin B12 preparations, and folate preparations.

Market Dynamics

Market Growth Drivers

Japan has one of the oldest populations in the world, with a large proportion of elderly citizens. Anemia is more common in older adults, and as the population continues to age, the demand for anemia drugs is expected to increase. According to 2020 estimates, over 28% of the Japanese population was over the age of 60, and 25.9% were over the age of 65, a proportion that is expected to rise to 29.1% in the next few years. Chronic kidney disease is a common cause of anemia. Japan has a high prevalence of chronic kidney disease, which is expected to contribute to the growth of the anemia drugs market. With better awareness and diagnostic tools, more cases of anemia are being identified and treated. This is expected to drive demand for anemia drugs in Japan. Pharmaceutical companies are actively developing new anemia drugs, which is expected to expand the product portfolio and increase competition in the market. This could result in increased innovation, improved efficacy, and lower prices for consumers. The Japanese government is taking steps to improve healthcare access and affordability, including expanding coverage for anemia drugs. This is expected to increase demand for these products.

Market Restraints

In Japan, the anemia drug industry is very competitive, and biosimilar copies of established drugs are becoming more common. This could put pressure on drug producers' prices and limit their profitability. Japan has stringent pharmaceutical laws, including a lengthy clearance process for new treatments. This can make bringing novel anemia treatments to market difficult and time-consuming for corporations. Erythropoiesis-stimulating agents (ESAs), in particular, can have substantial side effects, including an increased risk of heart attack and stroke. This has raised safety concerns and heightened regulatory attention. Anemia treatment is developing, with new techniques such as iron supplementation and blood transfusions being used. This could have a long-term influence on the market for anemia medications.

Competitive Landscape

Key Players

  • Pfizer
  • Astellas Pharma
  • Takeda Pharmaceutical
  • Daiichi Sankyo Company
  • Chugai Pharmaceutical
  • Otsuka Holdings Co.
  • Roche
  • Sumitomo Dainippon Pharma
  • Eisai
  • GSK

Healthcare Policies and Regulatory Landscape

The regulatory authority responsible for approving anemia drugs in Japan is the Pharmaceuticals and Medical Devices Agency (PMDA). The PMDA is a regulatory agency that operates under the jurisdiction of the Ministry of Health, Labour, and Welfare (MHLW). The PMDA is responsible for reviewing and approving pharmaceuticals, medical devices, and regenerative medicine products in Japan. It assesses the quality, efficacy, and safety of these products, and ensures that they meet the regulatory requirements for marketing in Japan. The PMDA operates a rigorous approval process for drugs, which involves a comprehensive review of clinical trial data and other relevant information. The agency also conducts post-marketing surveillance to monitor the safety and effectiveness of approved products and takes appropriate action if any safety concerns arise.

In addition to the PMDA, drugs in Japan are also subject to pricing and reimbursement regulations set by the MHLW. The MHLW sets reimbursement prices for drugs based on their therapeutic value and cost-effectiveness, and the prices are subject to periodic review and adjustment. This can impact the profitability of drug manufacturers and their ability to compete in the market.

Reimbursement Scenario

In Japan, anemia drugs are subject to pricing and reimbursement regulations set by the Ministry of Health, Labour and Welfare (MHLW). The MHLW sets reimbursement prices for drugs based on their therapeutic value and cost-effectiveness.

The reimbursement price for anemia drugs is based on a system called the National Health Insurance (NHI) drug price list. The NHI drug price list is revised every two years, and it considers the clinical benefits and economic impact of the drug.

Anemia drugs in Japan are classified into different categories, depending on their therapeutic use, and are subject to different pricing and reimbursement regulations. For example, erythropoiesis-stimulating agents (ESAs) are subject to a price revision every two years, based on their therapeutic value and cost-effectiveness. Iron supplements, on the other hand, are reimbursed at a fixed price, with no price revision.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Anemia Drugs Market Segmentation

By Type (Revenue, USD Billion):

  • Iron Deficiency
  • CKD (Chronic Kidney Disease)
  • Sickle Cell
  • Aplastic
  • Others

By Drugs

  • Dietary Supplements
  • Medicines

The types of nutritional supplements are further broken down into iron and vitamin supplements, among other categories, whilst the categories of medicines include antibiotics, hormones (erythropoietin), and chelation therapy (lead poisoning), among others.

By Distribution Channel (Revenue, USD Billion):

  • Hospital Pharmacy
  • Store Pharmacy
  • Online
  • Others

The distribution channel for anemia drugs in Japan is complex and multifaceted. Pharmaceutical companies must work with a variety of stakeholders, including hospital and retail pharmacies, distributors, and regulatory authorities, to ensure that their products are effectively distributed to patients who need them.

Insights10 will provide you with the reports within 10 key parameters which are:

  1. Market Overview
  2. Market Growth Drivers & Restraints
  3. Epidemiology of Disease Type
  4. Market Segmentation
  5. Market Share
  6. Competitive Landscape
  7. Key Company Profiles
  8. Healthcare Policies & Regulatory Framework
  9. Reimbursement Scenario
  10. Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

 

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

 

 

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and  Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.

 

 

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing the regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue/volume
  • ​Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


This report addresses

  • Intelligent insights to take informed business decisions
  • Qualitative, acute and result oriented market analysis
  • Market size and forecasts from 2022 to 2030
  • Opportunities for expansion and in-depth market analysis
  • Segmentation and regional revenue forecasts
  • Analysis of the market share and competitive landscape
  • Strategic Recommendations to chart future course of action
  • Comprehensive Market Research Report in PDF and PPT formats

Need more?

  • Ask our analyst how this study was put together to learn more
  • Discuss additional requirements as part of the free customisation
  • Add more countries or regions to the scope 
  • Get answers to specific business questions 
  • Develop the business case to launch the product
  • Find out how this report may influence your business revenue
Last updated on: 15 March 2023
Updated by: Riya Doshi

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up